PTJ
MLTX icon

Paul Tudor Jones’s MoonLake Immunotherapeutics MLTX Stock Holding History

Paul Tudor Jones’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$380K Buy
19,500
+4,100
+27% +$74.3K ﹤0.01% 2991
2026
Q1 		$287K Buy
+15,400
New +$255K ﹤0.01% 3167

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Paul Tudor Jones's MLTX Position: Q2 2026 in Review

Paul Tudor Jones reduced its MoonLake Immunotherapeutics (MLTX) stake by 4.6% in Q2 2026, selling an estimated $51.4K and leaving 58,740 shares worth $1.14M. The position accounts for ﹤0.01% of the portfolio, ranked #2322.

Paul Tudor Jones first reported a position in MLTX in Q2 2023 and has held it in 11 quarters since. The position peaked at $1.82M in Q4 2023. 171 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • Paul Tudor Jones held 58,740 shares of MoonLake Immunotherapeutics worth $1.14M as of Q2 2026.
  • Paul Tudor Jones sold 2,837 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $51.4K.
  • MoonLake Immunotherapeutics made up ﹤0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #2322 holding.
  • Paul Tudor Jones first reported a position in MoonLake Immunotherapeutics in Q2 2023 and has held it in 11 quarters since.
  • Paul Tudor Jones's MoonLake Immunotherapeutics position peaked at $1.82M in Q4 2023.
  • 171 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.